Literature DB >> 30151022

Stratus OCT Quality Control in Two Multi-Centre Multiple Sclerosis Clinical Trials.

John L Keltner, Kimberly E Cello1, Laura J Balcer, Peter A Calabresi2, Clyde E Markowitz3, John S Werner1.   

Abstract

The University of California (UC) Davis Reading Center evaluated 19,961 scans from 981 subjects in two multiple sclerosis therapeutic trials with the aim of determining the influence of optical coherence tomography quality control procedures on error rates. There was no optical coherence tomography technician certification in Trial 1, and technicians had very limited monitoring and feedback during the trial in view of the fact that data were received retrospectively. However, technicians were certified in Trial 2 and submitted data in accordance with the protocol. Trial 2 scans had higher signal strengths, fewer errors, and more useable data than the scans in Trial 1. Thus, certified technicians and prompt transmission of data for ongoing quality control monitoring provided higher quality data in multiple sclerosis trials.

Entities:  

Keywords:  OCT; multiple sclerosis; neuro-ophthalmology; quality control; reading centre

Year:  2011        PMID： 30151022      PMCID： PMC6104768          DOI： 10.3109/01658107.2011.557760

Source DB:  PubMed          Journal:  Neuroophthalmology        ISSN： 0165-8107


  28 in total

Review 1.  The ocular manifestations of multiple sclerosis. 1. Abnormalities of the afferent visual system.

Authors:  W I McDonald; D Barnes
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-09       Impact factor: 10.154

Review 2.  Optical coherence tomography: measuring in-vivo axonal survival and neuroprotection in multiple sclerosis and optic neuritis.

Authors:  Robert C Sergott
Journal:  Curr Opin Ophthalmol       Date:  2005-12       Impact factor: 3.761

3.  Relationship between retinal nerve fiber layer measurement and signal strength in optical coherence tomography.

Authors:  Carol Yim Lui Cheung; Christopher Kai Shun Leung; Dusheung Lin; Chi-Pui Pang; Dennis Shun Chiu Lam
Journal:  Ophthalmology       Date:  2008-02-21       Impact factor: 12.079

4.  Evaluation of image artifact produced by optical coherence tomography of retinal pathology.

Authors:  Robin Ray; Sandra S Stinnett; Glenn J Jaffe
Journal:  Am J Ophthalmol       Date:  2005-01       Impact factor: 5.258

5.  Relation of visual function to retinal nerve fiber layer thickness in multiple sclerosis.

Authors:  Jennifer B Fisher; Dina A Jacobs; Clyde E Markowitz; Steven L Galetta; Nicholas J Volpe; M Ligia Nano-Schiavi; Monika L Baier; Elliot M Frohman; Heather Winslow; Teresa C Frohman; Peter A Calabresi; Maureen G Maguire; Gary R Cutter; Laura J Balcer
Journal:  Ophthalmology       Date:  2006-01-10       Impact factor: 12.079

6.  The Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study system for evaluation of optical coherence tomograms: SCORE study report 4.

Authors:  Amitha Domalpally; Barbara A Blodi; Ingrid U Scott; Michael S Ip; Neal L Oden; Andreas K Lauer; Paul C VanVeldhuisen
Journal:  Arch Ophthalmol       Date:  2009-11

7.  Optical coherence tomography helps differentiate neuromyelitis optica and MS optic neuropathies.

Authors:  J N Ratchford; M E Quigg; A Conger; T Frohman; E Frohman; L J Balcer; P A Calabresi; D A Kerr
Journal:  Neurology       Date:  2009-07-28       Impact factor: 9.910

8.  Optical coherence tomography and disease subtype in multiple sclerosis.

Authors:  M Pulicken; E Gordon-Lipkin; L J Balcer; E Frohman; G Cutter; P A Calabresi
Journal:  Neurology       Date:  2007-11-27       Impact factor: 9.910

9.  Retinal nerve fiber layer axonal loss and visual dysfunction in optic neuritis.

Authors:  S Anand Trip; Patricio G Schlottmann; Stephen J Jones; Daniel R Altmann; David F Garway-Heath; Alan J Thompson; Gordon T Plant; David H Miller
Journal:  Ann Neurol       Date:  2005-09       Impact factor: 10.422

10.  Optic nerve atrophy and retinal nerve fibre layer thinning following optic neuritis: evidence that axonal loss is a substrate of MRI-detected atrophy.

Authors:  S Anand Trip; Patricio G Schlottmann; Stephen J Jones; Wai-Yung Li; David F Garway-Heath; Alan J Thompson; Gordon T Plant; David H Miller
Journal:  Neuroimage       Date:  2006-01-27       Impact factor: 6.556
View more
  5 in total

1.  Baseline retinal nerve fiber layer thickness and macular volume quantified by OCT in the North American phase 3 fingolimod trial for relapsing-remitting multiple sclerosis.

Authors:  Kimberly M Winges; John S Werner; Danielle J Harvey; Kimberly E Cello; Mary K Durbin; Laura J Balcer; Peter A Calabresi; John L Keltner
Journal:  J Neuroophthalmol       Date:  2013-12       Impact factor: 3.042

2.  Longitudinal optical coherence tomography study of optic atrophy in secondary progressive multiple sclerosis: Results from a clinical trial cohort.

Authors:  Kimberly M Winges; Charles F Murchison; Dennis N Bourdette; Rebecca I Spain
Journal:  Mult Scler       Date:  2017-11-07       Impact factor: 6.312

Review 3.  Vision and vision-related outcome measures in multiple sclerosis.

Authors:  Laura J Balcer; David H Miller; Stephen C Reingold; Jeffrey A Cohen
Journal:  Brain       Date:  2014-11-28       Impact factor: 13.501

Review 4.  Identification of posterior visual pathway lesions and MRI burden in people with Multiple Sclerosis.

Authors:  Tareef S Daqqaq
Journal:  Neurosciences (Riyadh)       Date:  2021-04       Impact factor: 0.906

5.  Optical coherence tomography outcomes from SPRINT-MS, a multicenter, randomized, double-blind trial of ibudilast in progressive multiple sclerosis.

Authors:  Robert A Bermel; Janel K Fedler; Peter Kaiser; Cindy Novalis; Jeff Schneebaum; Elizabeth A Klingner; Dawn Williams; Jon W Yankey; Dixie J Ecklund; Marianne Chase; Robert T Naismith; Eric C Klawiter; Andrew D Goodman; Christopher S Coffey; Robert J Fox
Journal:  Mult Scler       Date:  2020-10-15       Impact factor: 6.312
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.